New drug avoids treatment problem for hepatitis C patients

10/31/2006 | HealthDay News

Researchers say hepatitis C patients with cirrhosis and low platelet levels can take standard antiviral medications if they also use the new drug eltrombopag. Two common drugs, ribavirin and pegylated interferon, further reduce platelet levels in patients, but eltrombopag counters that effect.

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY